The objective of this study was to investigate the association between NSAID use and blood pressure (BP) among a sample of treated hypertensive patients. A controlled observational study was designed in UK primary care setting. Patients with diagnosed hypertension and currently being prescribed antihypertensive medication registered with four general practices, comparing patients also prescribed NSAIDs (exposed) to those not prescribed NSAIDs (unexposed). Majority of the patients were elderly. Systolic and diastolic pressure were the outcome measures. Data were collected for 184 NSAID users and 762 nonusers with a mean age of 68 years. There was no difference in either systolic (adjusted difference 1.9 mmHg, 95% CI À0.7 to 4.5, P ¼ 0.15) or diastolic (adjusted difference 1.0 mmHg, 95% CI À0.3 to 2.3, P ¼ 0.15) blood pressure. There was no evidence of any interactions according to categories of age, sex, or number of antihypertensive drugs prescribed. Among NSAID users, there was no evidence of any differences in blood pressure according to NSAID type or dose. In conclusion we found no evidence for an association between NSAID usage and BP control in known hypertensive patients receiving antihypertensive medication in primary care. The reported association between NSAID use and BP control appears much less substantial than has been previously suggested.
Introduction
Treated hypertension is common in the elderly. 1 Inadequate control is also common and a major cause of morbidity and mortality. 2 Although poor control may be due to various problems, there is some evidence 3 that coprescribing of drugs that may antagonise the effects of blood pressure (BP)-lowering drugs, in particular nonsteroidal anti-inflammatory drugs (NSAIDs) may be one explanation for poor control. Osteoarthritis (OA) is also common in the elderly and is the commonest comorbid condition in the elderly hypertensive population. 4 NSAIDs are commonly prescribed in OA despite other analgesics providing equivalent symptomatic relief. 5 Ibuprofen and diclofenac account for d80 million in general practice prescribing in England per annum (years 2001-2002) . 6 Antihypertensives and NSAIDs are frequently coprescribed, in up to 12% of community dwelling elderly. 7 There are biological reasons why NSAIDs might interact with antihypertensives. NSAIDs inhibit the synthesis of prostaglandins. Prostaglandins are naturally occurring vasodilators and interact with the reninangiotensin system. 4, [8] [9] [10] [11] Previous studies 4,9,10,12 on NSAIDs and hypertension have produced conflicting results and examined relationships between NSAID usage in nontreated and treated patients. Some NSAIDs (particularly indometacin and naproxen 4 may elevate BP and attenuate the effects of antihypertensives, on average being associated with 5 mmHg rise in mean BP. 9 Some evidence 4 suggests that this may not be a class effect and that not all NSAIDs (eg ibuprofen) will raise BP in this way. As hypertension and coprescribing of NSAIDs are common in the elderly, any adverse effects from coprescribing may potentially affect a substantial proportion of the elderly community. This reported 9 interaction of NSAIDs on BP could have an important clinical influence 13 in poorly controlled hypertensive patients taking BP-lowering drugs. Indeed, NSAIDs are listed 3, 14 as the most important 'antagonising agents' that clinicians need to consider when dealing with treated hypertensive patients who have poorly controlled BP readings. The aim of this study was to assess the impact on systolic BP (SBP) and diastolic BP (DBP) of coprescribing of NSAIDs in treated hypertensive patients in primary care.
Methods

Participants
Four practices in North Bristol agreed to participate. From each practice's computerised patient list, we identified patients with a Read code diagnosis of hypertension and currently on antihypertensive medication. Exposed cases were patients who additionally were prescribed NSAIDs around the time of sampling within the data collection period, and had at least one BP reading while on NSAIDs. Frequency matching by age and sex for each exposed patient, we selected four hypertensive patients not prescribed NSAIDs as unexposed controls. Patients with terminal illness or dementia were excluded. None was in long-term residential care. Ethical approval for the study was obtained from Southmead Hospital local research ethics committee.
Data collection
The four practices all use computer and paper patient records. Both formats were examined for every patient. Data were extracted by RS using a computerised data collection form, and data were anonymised at entry. The following data were collected: age, sex, past medical history, body mass index (BMI), current smoking and alcohol intake, antihypertensive drug usage by name, class and dose, aspirin and COX II (cyclooxygenase 2) inhibitor use, up to three BP measurements prior to initiating antihypertensive treatment, three BP readings measured most recent to study data collection and taken on separate occasions and while on antihypertensives, and NSAID usage where appropriate by name and dose. For the NSAID group, recent BP measurements were only included if the patient was being prescribed NSAIDs at the time. Data were collected from November 2001 to July 2003.
Sample size
The primary outcome was the mean of up to three most recent BP measurements. A total sample size of 930 would enable detection of a difference in BP of 0.23 s.d.'s (equivalent to 4 mmHg systolic and 2.5 mmHg diastolic), with 80% power and twosided 5% alpha and a ratio of four NSAID nonusers to every one NSAID user. This difference was based on meta-analysis 4 findings of up to 3 mmHg difference in mean BP for NSAIDs.
Analysis
Exposure was NSAID use and main outcomes were SBP and DBP. Characteristics of NSAID and non-NSAID groups were examined using appropriate descriptive statistics. Potential confounding variables were investigated using univariable associations with both NSAID use and BP. For the primary analysis, crude and adjusted differences in BP between groups were estimated using linear regression models. Secondary analyses were also conducted. Using appropriate interaction terms in the regression models, we investigated whether any association between NSAID use and BP differed according to age, sex, or number of antihypertensive drugs prescribed. For NSAID users, we investigated whether BP was associated with NSAID type. Lastly, we investigated whether there was any doseresponse association between NSAID use and BP. For this, we calculated the ratio of actual daily dose (ADD) to recommended defined daily dose (DDD) to identify patients being prescribed less than, equal to, or more than the recommended daily dose. DDD is an internationally recognised measure 15 that combines dose strength and frequency, and enables comparison between different drugs by assigning a value to each drug within a class. This represents the assumed average maintenance dose per day for a drug used for its main indication in adults. All secondary analyses used multivariable linear regression, with interaction terms in the models as appropriate. The effect of clustering by practice was taken into account in the initial analyses, but as results were not materially different from the unadjusted analyses, results from the simpler models are presented.
All analyses were conducted using Stata version 8.
Results
Data were collected for a total of 946 patients, of whom 184 were prescribed NSAIDs. The mean age was 68 years.
Group comparisons
The NSAID group had slightly lower mean preantihypertensive treatment DBP and increased aspirin use, and as expected, a larger proportion with musculoskeletal problems (Table 1) . Otherwise the groups were well matched for comorbidity, age, sex, BMI, smoking, and alcohol usage.
Primary outcomes
There was no evidence of any difference between NSAID users and nonusers in either systolic (adjusted difference 1.9 mmHg, 95% CI À0.7 to 4.5, (Table 2) .
Interactions
There was no evidence that the relation between BP and NSAID usage differed according to age, sex, or number of antihypertensive drugs prescribed.
NSAID subgroups
Ibuprofen and diclofenac together accounted for over 75% of the NSAIDs used (Table 3) . Indometacin may be associated with higher SBP but confidence intervals are wide.
Others used included etodolac, fenoprofen, nabumetone, piroxicam, sulindac, tiaprofenic acid, and diclofenac plus misoprostol combinations, and they may be associated with higher DBPs. Otherwise, there was no evidence that either SBP (P ¼ 0.17) or DBP (P ¼ 0.19) differed according to type of NSAID prescribed (Table 3) .
Dose-response relationship
Of the patients on NSAIDs, fewer than half were prescribed the equivalent of the DDD (Table 4) . ADD:DDD ratio ranged from 0.25 to 2. That is, patients were prescribed between one-quarter and twice the recommended daily dosage for any NSAID. There was no evidence of a dose-response relationship between ADD:DDD ratio and SBP and DBP. For a doubling of the ADD:DDD ratio, SBP changed by À1.6 mmHg (adjusted 95% CI À5.7 to NSAID and BP control in treated hypertensives R Sheridan et al 2.5, P ¼ 0.45) and DBP changed by À0.5 mmHg (adjusted 95% CI À2.6 to 1.7, P ¼ 0.67).
Discussion
Principle findings
NSAID usage was not found to be associated with inadequate control of hypertension. The magnitude of any effect is unlikely to be clinically important although the upper 95% confidence limits do not exclude meaningful effects for SBP ( þ 4.5 mmHg) and DBP ( þ 2.3 mmHg). Our results do not appear to suggest that concurrent NSAID usage is an important factor for inadequate BP control. Recent guidelines and evidence-based texts 3, 14, 16 list NSAIDs as BP antagonists, but this study shows that the magnitude of effect appears marginal at best. Furthermore, there was no evidence for a positive dose-response relationship between increasing ADD and worsening BP control (Table 4) .
Strengths and weaknesses
This large study was adequately powered to detect what were deemed a priori to be clinically important differences in BP. It is community based and includes a large proportion of elderly patients with high comorbidity -the most relevant group in terms of a potentially important clinical interaction between NSAIDs and BP control. Lastly, we controlled for potential confounders in both study design and analysis.
Our results rely on documented BP readings being accurate and unaffected by single-digit preference, although any effect should be similar in both groups, so that differential misclassification is unlikely. The study design did not allow for compliance with either antihypertensive medication or NSAIDs. Other potential confounders not allowed for are renal function, salt intake and exercise. In one metaanalysis, 4 adjusting for salt intake reduced the effects of naproxen on BP from 6.1 to 3.7 mmHg. Exercise is unlikely to be a confounder here. It is possible that NSAID use may be inversely associated with exercise, and it is known that regular physical activity can reduce BP. However, in order for exercise to have a confounding effect in this study, there would need to be an inverse association between NSAIDs and BP. We did not record ethnicity, which can influence hypertension and response to drugs, however patients in the four participating GP practices were drawn from largely Caucasian populations. We have not controlled for over-the-counter NSAID usage. In the elderly, this is not likely to be important because of free entitlement to over 60-year-olds. We did not control for duration of NSAID usage although the majority of patients were on NSAIDs long enough to have had two or more BP readings on separate occasions measured in this time. The study is retrospective and observational and so potentially not as robust as a prospective blinded study. It is possible that patients with musculoskeletal disease visit their GP more often and so have BP measured and treated more intensively. We have not controlled for this; however, the results show that both groups had similar number of antihypertensive agents prescribed and so this is unlikely to be a factor.
Biological plausibility for and against interaction of NSAIDs and BP control
It has been proposed that NSAIDs might plausibly affect BP in several ways. In terms of drug-disease interactions, prostaglandins can potentially have both vasopressor and depressor actions. NSAIDS may elevate BP through a decrease in prostaglandininduced renal vasodilatation, sodium retention, alteration in responsiveness to angiotensin-II and (16) 84 (9) ADD, Actual daily dose (total daily dose actually prescribed); DDD, defined daily dose (internationally recognised value representing the assumed average maintenance dose per day for a drug used for its main indication in adults). 15 renin, and vasoconstriction. 4, 10, 11 However, NSAIDs may reduce BP in patients with high renin hypertension. 17 There are also concerns that NSAIDs may be a cause for developing hypertension; in a recent important large (80 000 women) prospective observational study 18 their use was associated with increased risk of developing hypertension in younger women. In relation to drug-drug interactions, NSAIDs may antagonise angiotensin-converting enzyme inhibitors (ACE-I), angiotensin-II receptor antagonists, diuretics and beta-blockers. 8, 9, 12, 14 There is some evidence 19 that NSAIDs do not antagonise calcium channel blockers. In sum, the weight of biological evidence appears to suggest an adverse effect of NSAIDs on BP control.
Context of other studies
Previous systematic reviews and meta-analyses 4, 9 investigating the effects of NSAIDs on BP control have produced conflicting results. Furthermore, there are many methodological shortcomings to the small individual studies included in these systematic reviews. Many excluded older patients, had short follow-up periods, studied normotensive volunteers or were underpowered to detect the relatively small differences in BP shown. One meta-analysis 4 that included 1213 hypertensives aged 28-62 years showed that indometacin and naproxen were associated with an average rise in mean arterial pressure of 3.6 and 3.7 mmHg, respectively, after adjusting for salt intake (4.8 and 6.1 mmHg unadjusted). However, other NSAIDs including ibuprofen had no effect on BP in hypertensives. A further systematic review and meta-analysis 9 suggested that NSAIDs elevate mean BP by 5 mmHg. However, when individual NSAIDs were examined, only piroxicam with 27 individuals taken from four trials had strong evidence of an association. Of note, a single pharmaceutical company supported nearly half of the uncontrolled studies included in the systematic review.
We also found two additional cross-sectional reports and one subgroup analysis of a randomised-controlled trial (RCT). 7, 10, 20 The first crosssectional study 10 found a 5 mmHg higher SBP (though 95% CI were -0.02 to 9.74) but no effect on DBP in those taking NSAIDs. They studied 235 noninstitutionalised people aged over 65 years currently on NSAIDs with matched controls. There was also insufficient control of important confounding factors (pretreatment BP, salt intake, comorbidity, smoking and alcohol). A second cross-sectional study 7 suggested that NSAID usage might be an independent risk factor for the presence of hypertension. They looked at 2800 elderly noninstitutionalised patients and found 26% were prescribed NSAIDs and 12% taking them concurrently with antihypertensive medication. After adjusting for confounders they found NSAID usage predicted the presence of hypertension (odds ratio of 1.4). Finally, in the MRC Hypertension in older adults RCT, 21 NSAID usage prevalence was 14%, aspirin being included as an NSAID and the entry criteria being previously untreated hypertension. In reanalysis of a large subgroup, 20 NSAID use was not associated with BP level. This more methodologically rigorous study supports the findings from our own study that NSAID usage is not likely to have an important clinical effect. Given the limitations of previous research, particularly in terms of inadequate sample size and recruitment of noncommunity-based cases and controls, we feel that our larger, community-based study, that was adequately powered, and included a large proportion of elderly patients adds important evidence to the debate around the association of NSAID usage and BP control in treated hypertensive patients.
Future studies
As coprescribing of antihypertensives and NSAIDs is common and the 95% confidence limits from our own study cannot fully rule out a small, but potentially important difference between NSAID usage and BP control (Table 2) , further studies should address the potential interaction in prospective cohort studies, controlling for all potential confounders, including compliance and duration of treatment, in community-based individuals.
Conclusions
We found no evidence of any important effect of NSAIDs on BP control in known hypertensive patients receiving antihypertensive medication. Although the confidence intervals for SBP and DBP include the null, the upper limits do not rule out a small but potentially important association between NSAIDs and inadequate control. However, given that conventional criteria used to assess causality are not satisfied, the case for a causal association between NSAIDs and poor BP control is far from proven. While it might be premature to change guideline recommendations, 14, 22 which advise review of coprescribing of NSAIDs in poorly controlled hypertensive patients, it seems that the clinical importance of such an association is much less than previously suggested. If patients in primary care have inadequate control of their BP, other reasons for inadequate control, such as measurement error, 'white coat' hypertension, poor adherence to therapy and progressive disease may be more likely reasons for inadequate control (Table 5) . 3 
